Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472112 | 0.84 | TDP1 (1.00) | TDP1TSHRSMN1; SMN2HSD17B10POLB | |
| SCHEMBL700469 | 0.78 | TSHR (1.00) | TDP1TSHRSMN1; SMN2HSD17B10POLB | |
| SCHEMBL28313474 | 0.78 | TSHR (1.00) | TDP1TSHRSMN1; SMN2HSD17B10POLB | |
| SCHEMBL9550119 | 0.78 | TDP1 (0.78) | TDP1TSHRSMN1; SMN2HSD17B10POLB | |
| SCHEMBL7531431 | 0.78 | TDP1 (0.54) | TDP1TSHRSMN1; SMN2HSD17B10POLB | |
| SCHEMBL29538967 | 0.78 | TSHR (1.00) | TDP1TSHRSMN1; SMN2HSD17B10POLB | |
| SCHEMBL10379786 | 0.78 | HSD17B10 (0.54) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL25105 | 0.78 | HSD17B10 (0.54) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL28554564 | 0.78 | HSD17B10 (0.54) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| Water SCHEMBL27940548 | 0.78 | TDP1 (0.69) | TDP1TSHRSMN1; SMN2HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810001-B | Synthesis method of ropinirole hydrochloride intermediate 2-methyl-3-nitrophenylacetic acid | 深圳市第二人民医院 | 2022-04-01 | — | — | CN | claimed |
| CN-106588788-A | Method for synthesizing 1,2,3-triazole compound through one-pot two-step method | 河南师范大学 | 2017-04-26 | — | — | CN | claimed |
| JP-7233126-A | — | — | None | — | — | JP | disclosed |
| WO-2023202625-A1 | FGFR2 INHIBITOR AND METHOD FOR USING SAME | 深圳福沃药业有限公司 | 2023-10-26 | — | — | WO | disclosed |
| CN-116903628-A | FGFR2 inhibitors and methods of use | 深圳福沃药业有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-109810001-B | Synthesis method of ropinirole hydrochloride intermediate 2-methyl-3-nitrophenylacetic acid | 深圳市第二人民医院 | 2022-04-01 | — | — | CN | disclosed |
| CN-105849082-B | The manufacturing method of nitro compound | 住友化学株式会社 | 2018-07-13 | — | — | CN | disclosed |
| EP-3088382-B1 | METHOD FOR PRODUCING NITRO COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-07-11 | — | — | EP | disclosed |
| CN-106588788-A | Method for synthesizing 1,2,3-triazole compound through one-pot two-step method | 河南师范大学 | 2017-04-26 | — | — | CN | disclosed |
| US-9561998-B2 | Method for producing nitro compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160318846-A1 | METHOD FOR PRODUCING NITRO COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| CN-101675061-A | pyrrolo-N-heterocyclic derivatives, process for their preparation and their use in medicine | SHANGHAI HENGRUI PHARM CO LTD | 2010-03-17 | — | — | CN | disclosed |
| EP-2157093-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-02-24 | — | — | EP | disclosed |
| CN-101307052-A | Method for preparing pyrrole-N-heterocyclic ring derivates and medical application thereof | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2008-11-19 | — | — | CN | disclosed |
| CN-101219955-A | Method for synthesizing o-nitrobenzaldehyde compounds | SHANGHAI CHEMPARTNER CO LTD (CN) | 2008-07-16 | — | — | CN | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| JP-H07233126-A | IODOANILINE DERIVATIVE AND ITS PRODUCTION | NISSAN CHEM IND LTD | 1995-09-05 | — | — | JP | disclosed |
| US-5200544-A | Acid generator, acid sensitive polymer; photosensitivity | AT&T BELL LABORATORIES (US) | 1993-04-06 | — | — | US | disclosed |
| US-5135838-A | Resin sensitive to UV radiation and a nitrobenzyl compound that generates an acid | AT&T BELL LABORATORIES (US) | 1992-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318846-A1 | METHOD FOR PRODUCING NITRO COMPOUND | NOS1, NOS3, NOS2 | TDP1 3246/4885TSHR 1679/4885SMN1; SMN2 2329/4885 |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | MTOR, PKN2, MAP3K15 | TDP1 1598/4885TSHR 3388/4885SMN1; SMN2 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.